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Abstract. Primary liver tumours have a high incidence and 
mortality. The most important forms are hepatocellular carci-
noma and intrahepatic cholangiocarcinoma, both can occur 
together in the mixed phenotype hepatocellular-cholangio-
carcinoma. Liver progenitor cells (LPCs) are bipotential stem 
cells activated in case of severe liver damage and are capable 
of forming both cholangiocytes and hepatocytes. Possibly, 
alterations in Wnt, transforming growth factor-β, Notch and 
hypoxia pathways in these LPCs can cause them to give rise 
to cancer stem cells, capable of driving tumourigenesis. In this 
review, we summarize and discuss current knowledge on the 
role of these pathways in LPC activation and differentiation 
during hepatocarcinogenesis.
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1. Introduction
Liver cancer is one of the most frequently diagnosed cancers 
worldwide. Despite efforts made, these tumours are often 
detected in an advanced stage, making liver cancer the third 
most deadly cancer worldwide (1). The most important types 
of primary liver cancer are hepatocellular carcinoma (HCC) 
and intrahepatic cholangiocarcinoma (ICC). HCC often 
develops in a background of chronic liver disease caused by 
chronic alcohol abuse, viral hepatitis or non-alcoholic steato-
hepatitis, while less is known on potential risk factors for ICC. 
Both primary tumours can be found together in combined 
hepatocellular-cholangiocarcinoma (CHC), which is charac-
terised by a worse prognosis than HCC or ICC (2,3). There are 
several curative therapeutic options for primary liver tumours 
including resection, transplantation and radiofrequency abla-
tion. However, more often than not, these tumours are detected 
in late stages. At this point, existing therapies including anti-
angiogenic compounds such as sorafenib, and transarterial 
chemoembolisation (TACE) (4), mainly aim to slow down 
tumour growth and increase survival. Unfortunately, these 
treatment strategies still hold various serious adverse effects 
and therapy resistance, relapse and metastasis remain a real 
threat (4-6). Importantly, anti-angiogenic treatment also 
sometimes causes increased local invasion and metastasis, 
worsening tumour progression (5). Finally, a phenotypic 
switch from HCC to CHC has been reported after both TACE 
and increased hypoxia inducible factor (HIF) stabilisation in a 
mouse model for HCC (6,7).
Cancer stem cells (CSC) are cancer cells that possess stem 
cell characteristics such as the ability to differentiate to all 
cell types found in a particular cancer sample and are associ-
ated with relapse and metastasis (8,9). Recently, interest has 
grown in the existence of liver CSC with a liver progenitor 
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cell (LPC) gene signature, LPCs are triggered during severe 
acute or chronic liver injury, during which proliferation of 
mature hepatocytes is inhibited (10). LPC-progeny can express 
hepatocyte- or cholangiocyte-specific lineage markers and 
experimentally have been proven to differentiate into either of 
these cell types (11-13).
Possibly, adverse effects often seen following treatment 
could be caused by survival and adaptation of LPC derived 
CSC. This would indicate that LPCs could not only play a 
role in tumour initiation, but also in progression and therapy 
resistance (14-17).
This review briefly summarizes the current knowledge 
on signalling pathways acting in primary liver tumour 
biology, specifically their involvement in LPC activation and 
proliferation, as well as a possible relation between LPCs 
and CSCs.
2. Liver progenitor cells
In case of severe hepatic damage, such as in elaborate 
chronic liver injury, when proliferation of hepatocytes and/or 
cholangiocytes alone is insufficient to restore the liver mass 
and function, liver progenitor cells (LPCs) are stimulated 
to proliferate and replace the damaged cell types (12). Even 
though LPCs can most commonly be found in the canals of 
Hering (18,19), several other possible locations have been 
described: intralobular bile ducts, peri-ductal cells and peri- 
biliary hepatocytes (20). Possibly, the LPC niche also consists 
of other actors in liver damage, such as hepatic stellate cells 
and Kupffer cells (21-23). Differential interaction with these 
cells could account for the different observations concerning 
LPC location and factors involved in their activation in various 
models of liver injury (19,22,23).
The most commonly used markers for identification of 
LPCs, or determination of cells with LPC-like characteristics 
are Prominin 1 (CD133), epithelial cell adhesion molecule 
(EpCAM), α-fetoprotein (AFP), and (cyto-) keratin 19 (CK19). 
However, many other stem cell, hepatic and cholangiocytic 
markers are used to characterize LPCs (Table I) (24-26).
Although the existence of LPCs and their role in liver 
injury is generally accepted, and a broad range of markers is 
being used to identify and/or isolate these cells from livers 
(13,19,27-29), researchers have not yet agreed on a precise set 
of markers defining the LPC population, therefore filtering out 
the identity of the ‘true progenitor cell’, remains a challenge.
3. Liver progenitor cells in hepatic carcinogenesis
Several studies have shown that cells with LPC characteristics 
are part of the tumour niche in primary liver tumours (30-32). 
Because of their multipotent characteristics there probably is 
a role for LPCs in HCC and ICC formation, however, due to 
the dual hepatocytic and cholangiocytic origin, it is the CHC 
that is generally presumed to be a progenitor derived tumour 
(30,33).
Currently, there are two major hypotheses on how stem 
cells influence tumour formation. Firstly, the clonal evolution 
model, which presumes that a single cell acquires random 
mutations and gives rise to a group of identical tumour cells, 
each with equal potential to generate a tumour. Secondly, the 
cancer stem cell theory proposes that a tumour consists of a 
heterozygous cell population, where only certain cells are able 
to self-renew and differentiate (9).
Over the years, CSC have been shown to play a role in the 
development of certain forms of leukaemia and glioblastoma, 
as well as in several solid tumours such as breast, gastric and 
colon cancer (15,24,34) and are now being extensively studied 
in hepatocarcinogenesis (15,24).
The predisposition of primary liver tumours to develop 
in a background of chronic liver disease in which there is an 
increased proliferation of progenitor cells (2,7) increases the 
likelihood of progenitor cells accumulating and stabilising 
enough mutations to obtain a cancerous phenotype. It may 
thus be possible for LPCs to transform into (hepatic) cancer 
stem cells and grow into primary liver tumours (15,24).
So far, several pathways have been shown to mediate LPC 
activation, proliferation and/or differentiation. The balance 
between Wnt and Notch signalling has been proposed to be 
crucial for determination of the LPC cell fate. Activation of the 
Notch pathway is essential for biliary differentiation, as shown 
by several in vivo and in vitro experiments (35,36). Moreover, 
in case of hepatocyte injury, activation of the canonical Wnt 
pathway, probably prevents activation of the Notch pathway, 
thus pushing LPC differentiation towards hepatocytes (35,36). 
Also, interaction between tumour cells and the extracellular 
matrix (ECM) is shown to be essential for tumour progres-
sion, invasion and metastasis, transforming growth factor-β 
(TGF-β)-mediated epithelial mesenchymal transition (EMT) 
plays an important role in this interaction (37). Recently 
TGF-β signalling has also been linked to the presence of LPCs 
in hepatocarcinogenesis (38).
The Notch, Wnt and TGF-β pathways are also well known 
to be involved in many tumourigenic processes. In this review 
we will focus on these three pathways and discuss their role in 
hepatocarcinogenesis, with special attention to their potential 
involvement in LPC and/or CSC-mediated tumour initiation 
and progression (Fig. 1).
Wnt/β-catenin pathway. The canonical Wnt signalling 
pathway directs essential cell regulatory mechanisms such as 
cell proliferation and cell polarity, but also plays an important 
role during embryonic development (39-41).
A key player in the canonical Wnt signalling pathway is 
β-catenin, which also plays a crucial role in intracellular junc-
tions by forming a receptor complex with epithelial cadherin 
(E-cadherin) (39). Upon binding of Wnt to its receptor 
Frizzled, β-catenin switches from being part of a destruction 
complex to the formation of a ‘Wnt-signalosome’ that prevents 
β-catenin degradation. This allows the latter to migrate 
to the nucleus where it binds to the T-cell factor/lymphoid 
enhancer factor and induces transcriptional activation of 
Wnt-responsive genes (39,42). This β-catenin signalling has 
been shown to be necessary for mouse LPC activation upon 
injury in rodents (43) and to regulate the hepatocytic specifi-
cation of LPCs (35).
In HCC cell lines, activation of the Wnt/β-catenin signal-
ling pathway not only increases EpCAM accumulation in 
both the cytoplasm and the nucleus (42), but also increases the 
EpCAM+AFP+ and the oval cell marker 6 (OV6)+ population. 
These represent cell populations with strong LPC features 
INTERNATIONAL JOURNAL OF ONCOLOGY  44:  1015-1022,  2014 1017
which also demonstrate tumourigenic and invasive capacities 
(41,44). Canonical signalling probably also plays a role in 
chemoresistance, which is strongly linked to LPC prolifera-
tion (45,46), as shown by the increased EpCAM expression in 
patients with reduced sensitivity to interferon α/5-fluorouracil 
combination therapy (46). In addition, blocking the Wnt/β-
catenin pathway not only inhibits HCC cell growth (42), but 
also diminishes chemoresistant OV6+ colonies (41).
Interestingly, canonical and non-canonical Wnt pathways 
seem to have opposing effects on tumour growth (47-49). The 
canonical pathway (mediated by Wnt1-3) mediates growth and 
regeneration and is reported activated in well differentiated 
HCC cells while it is repressed in poorly differentiated HCC 
cell lines (41,43,49). Oppositely, activating the non-canonical 
pathway (including Wnt5a and 11) has been shown to inhibit 
HCC and ICC growth (47-49), possibly by antagonizing the 
canonical pathway, and promoting cell motility and invasion 
(49). This could indicate an important role in the growth and 
migration pattern of the tumour, caused by interaction between 
these two pathways during hepatocarcinogenesis.
Transforming growth factor-β pathway. TGF-β is involved in 
various cellular functions, such as cell growth, differentiation 
and apoptosis, both in adult as well as in embryonic stages (50). 
Binding of TGF-β to its receptor results in phosphorylation of 
the receptor eventually followed by the translocation of Smad 
proteins (Smad2/3) to the nucleus in a complex with Smad4 
(coSmad), where they can regulate transcription by binding 
to Smad-binding elements in co-operation with a plethora of 
Smad interacting proteins (51,52). However, TGF-β also uses 
non-Smad signaling pathways such as the phosphoinositide 
3-kinase/Akt/mTOR pathway, the p38 and Jun N-terminal 
kinase/mitogen-activated protein kinase pathway to transduce 
its signals (53). In addition to these non-canonical pathways, 
TGF-β signalling is regulated at many levels by processes 
such as endocytosis of the receptor complex, or by molecules 
like inhibitory Smads6/7 and the bio-activity of the ligands 
through proteolytic cleavage by their protease (mainly 
furin) (51).
Like its regulation, the role of TGF-β in tumour formation 
is rather complicated. In healthy tissue, it acts as a tumour 
Table I. Selection of LPC markers and their potential role in hepatocarcinogenesis.
Abbreviation Full name Role in HCC and/or CC development
CK7 (cyto) keratin 7 Increased expression of these cholangiocytic markers in primary liver
CK19 (cyto) keratin 19 tumours indicate poor prognosis (16,87)
ALB Albumin Hepatocyte-specific marker, upregulated in ICC, compared to other 
  cholangiocellular tumours like extrahepatic cholangiocarcinoma (88,89)
OPN Osteopontin Restricted to cholangiocytes lining the canals of Hering, good LPC marker 
  for lineage studies (12)
OCT4/Pou5f1 Octamere binding transcription Embryonic transcription factor involved in stem cell self-renewal. Possible
 factor/Pou domain class 5, prognostic marker for HCC, and upregulated in chemoresistant liver cancer 
 transcription factor 1 cells (90)
AFP α-fetoprotein Fetal serum protein, often but not always re-expressed in HCC and CHC 
  (89,91)
LIF Leukemia inhibitory factor Cells are pushed to differentiate during decreased LIF levels. LIF is elevated 
  in LPCs and known to induce acute phase proteins in hepatocytes (92).
Sox 9 SRY-related HMG box Transcription factor involved in cholangiocyte-specific development (93)
 transcription factor 9
CD133 Prominin 1 Cancer stem cell marker, upregulated in most primary liver cancers.
  Associated with more aggressive phenotype and therapy resistance (94-96)
CD34 CD34 antigen Cancer cell marker mainly expressed in early hematopoietic cells.
CD44 CD44 antigen Upregulated in most primary liver cancers, regulation associated with more
  aggressive phenotype and treatment resistance (96)
CD56/NCAM Neural cell adhesion molecule Shift from E-cadherin to NCAM expression indicates epithelial- 
  mesenchymal transition
CD117 c-Kit Proto-oncogene, upregulation due to mutation occurs in many tumours.
  C-Kit inhibition is also reported to slow LPC expansion and tumour
  formation in rodents (97)
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suppressor controlling the cell cycle, inducing apoptosis and 
regulating autophagy. During tumourigenesis, cells switch 
their response to TGF-β, making it a potent inducer of cell 
motility, invasion and metastasis, as well as guardian of stem 
cell maintenance (54). In liver carcinogenesis, TGF-β has 
been shown to have both tumour suppressing and promoting 
effects (24,50) and its expression is decreased in early, while 
increased in later stages of tumourigenesis (24,55,56).
TGF-β signalling is also a master regulator of initiating 
and maintaining EMT, the process directing cancer cells 
towards invasion and metastasis (37). In HCC cells, inhibition 
of TGF-β has been reported to upregulate epithelial-cadherin 
(E-cadherin) and thereby lower migration and invasion 
potential (57). However, in human fetal hepatocytes (cells 
carrying progenitor cell features, like EpCAM and CK19 as 
well as hepatoblast features like AFP), TGF-β even induces 
apoptotic, growth inhibitory signals, as well as pro-invasive, 
mesenchymal characteristics such as neuronal cadherin, Snail 
and vimentin (57). What is more, during EMT, TGF-β signal-
ling results in dissociation of β-catenin from the E-cadherin/ 
β-catenin membrane complex resulting in cytoplasmatic and 
nuclear accumulation of β-catenin and subsequent activation 
of the Wnt pathway (58). Possibly, this upregulation of the 
Wnt pathway, due to TGF-β dysregulation causes a larger 
population of activated LPCs in HCC patients (59) and in mice 
following partial hepatectomy (60). Furthermore, in patients, 
high nuclear β-catenin accumulation is correlated with higher 
vascular invasion grades and increased recurrence after trans-
plantation (59).
These data suggest an important, but contradictory role for 
TGF-β signalling in hepatocarcinogenesis, possibly regulating 
the activation and differentiation of LPCs, through regulation 
of the Wnt-signalling pathway. Because of the important role 
of TGF-β in EMT, its regulation is decisive for the invasive 
and metastatic potential of the tumours.
Notch pathway. The Notch pathway is important in stem cell 
self-renewal, differentiation, and plays a special role in the 
control of many binary cell fate choices in embryonic and adult 
cells (61). In the liver, Notch signalling promotes differentia-
tion of LPCs towards the cholangiocytic lineage rather than 
to hepatocytes (62). Furthermore, Notch is involved in several 
fundamental cell regulatory processes such as proliferation, 
apoptosis and EMT (61). Binding of Delta or Jagged ligand 
to the Notch receptor, causes cleavage of the extracellular 
C-terminal peptide. Notch intracellular domain (NICD) is 
then cleaved by γ-secretase, releasing it into the cytoplasm 
so it can migrate to the nucleus, bind to CSL, recruit co-acti-
vators such as mastermind-like, and induce Notch-dependent 
gene transcription. The two major targets are the Hairy and 
Figure 1. Schematic representation of the role of Wnt, Notch, TGF-β and Hif-1α signalling in hepatocytes, cholangiocytes and liver progenitor cells in 
hepatocarcinogenesis. The cell growth promoting effects of the Wnt and Notch pathways on hepatocytes and cholangiocytes, respectively, as well as their 
differential role on liver progenitor cells. The complicated dual role of TGF-β as guardian of cell cycle control, as well as its tumour promoting and invasion 
and metastasis inducing potential in all cell types is visualised. Finally, the complex interactions between these three pathways, and the possible influence of 
the HIF-1 pathway is presented.
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Hes-related repressor protein families of transcription factors 
(61,63).
Like the Wnt and TGF-β pathway, aberrant Notch signal-
ling is well described in many different kinds of cancer, such 
as breast, lung, colorectal, pancreatic and hepatic cancer 
(24,63). However, deregulation of the Notch pathway has 
been described as both oncogenic and tumour suppressive, 
depending on tissue type and circumstances (63-65).
For example, the effect of Notch signalling on hepatocar-
cinogenesis can be determined by its effect on several players 
in cell cycle control such as p53 (65), cyclin-A, -D1 and -E (64). 
Induction of p53 in HepG2 cells, leads to an increased expres-
sion of NICD and downregulation of the cells proliferative 
capacity, but not the other way around. Moreover, in cells 
expressing mutant p53, not able to induce NICD upregula-
tion, administration of recombinant NICD protein did cause 
reduced proliferation (65).
In a different HCC cell line, SMMC7721, NICD overex-
pression by retroviral transfection did cause increased p53 
levels, as well as decreased levels of proteins involved in cell 
cycle control, like phosphorylated forms of the retinoblastoma 
protein, thus also causing inhibition of growth and prolifera-
tion (64). Unfortunately neither of these studies investigated 
the LPC properties of the used cells, before nor after p53 or 
NICD induction.
In accordance, Notch pathway inhibition by DAPT 
(γ-secretase inhibitor) in adult mice after conditional deletion 
of retinoblastoma protein family genes in the liver, which 
causes proliferation of the progenitor compartment, resulted 
in an increased number of HCC nodules (66). Also, over-acti-
vation of NICD inhibits cell proliferation in tumour cell lines 
derived from these retinoblastoma-deficient mice, but not in 
HepG2 cells (66). These data suggest a differential role for the 
Notch pathway in progenitor cells compared to hepatocytes, 
further supported by recent findings of hepatocyte-specific 
NICD overexpression causing development of HCC with 
100% penetrance after 12 months (67) and ICC after partial 
hepatectomy (68).
Finally, Notch signalling has also been related to therapy 
resistance; Delta-like ligand induced activation of the Notch 
pathway seems to mediate tumour resistance to anti-angio-
genic therapy by activating escape mechanisms in the tumour 
causing the formation of new vessels circumnavigating the 
therapy-induced blockage (69,70).
4. Role of hypoxia in hepatic carcinogenesis and progenitor 
cell activation
In the presence of oxygen, HIF is quickly hydroxylated by 
prolyl hydroxylase domain proteins, causing degradation. 
However, in hypoxic conditions, shortage of hydroxyl-groups 
leads to HIF stabilisation and migration to the nucleus where 
it regulates processes supporting cell survival under hypoxic 
conditions, for example by increasing (neo)angiogenesis 
(71). Primary liver tumours, especially HCC, often develop 
in a background of chronic liver disease, characterised by 
fibrogenesis, eventually leading to cirrhosis. This process is 
accompanied by increased hypoxia, caused by sinusoidal 
capillarisation and formation of fibrotic septa increasing resis-
tance to blood flow and thus decreasing oxygen delivery to 
liver cells. In addition, the fast growing liver tumours quickly 
outgrow the existing liver vascularisation, thus creating 
hypoxic conditions (7,72,73).
Current treatment strategies for advanced stage liver 
cancer, such as anti-angiogenic treatment or TACE, often 
aim to deprive the tumour of its blood and nutrient supply (4). 
However, therapy resistance to TACE and anti-angiogenic 
treatment has been attributed to induction of hypoxic condi-
tions and activation of HIF (3,7,74), by adversely increasing 
cancer cell survival and tumour growth.
Recently, a significant increase in stem cell marker expres-
sion has been seen in vitro after exposure of HCC cultures 
to hypoxia (75). Possibly, the decreased oxygen levels in 
tumour cells stimulate dedifferentiation towards a progenitor 
phenotype. Potentially increased proliferation and altered 
differentiation of LPCs in HCC also cause the phenotypic 
switch to CHC in prolyl hydroxylase domain 2 heterozygous 
mice, which are characterised by increased HIF stabilisation 
(3,7) and in patients, after receiving TACE treatment (6).
These findings have raised many questions about the future 
of these therapies, since monotherapies are often insufficient 
in treatment of HCC and can even induce more aggressive 
disease. It is of vast importance to consider alternative thera-
peutic strategies that prevent this massive hypoxic response. 
For example, a recent study has shown a better outcome in 
mice with HCC, after treatment with anti-placental growth 
factor, causing vascular normalisation, instead of blocking 
neoangiogenesis, and thus causing less hypoxia (3). Also, 
administration of EF24, could synergistically enhance 
the antitumour effects of sorafenib, reduce metastasis and 
overcome sorafenib resistance through inhibiting HIF-1α by 
sequestering it in the cytoplasm and promoting degradation by 
upregulating the Von Hippel-Lindau tumour suppressor in five 
different cell lines and in both xenograft and orthotopic mouse 
models for HCC (76).
Possibly, a HIF-dependent alterations to the Wnt, Notch 
and/or TGF-β pathways are responsible for the observed 
reaction of tumour tissue to hypoxia inducing therapies. Both 
in vitro and in vivo experiments have shown crosstalk between 
the Wnt and HIF pathways, depletion of β-catenin resulted 
in more severe hepatic injury in a mouse model for liver 
perfusion while an increased Wnt signalisation resulted in a 
marked decrease of hepatic injury compared to control (77). 
In this study, Wnt1 overexpression resulted in a significant 
higher response of HIF sensitive genes and HIF1α protein 
levels, While β-catenin/T-cell factor target gene expression 
was significantly reduced after ischemia, without a decrease 
in total β-catenin. The observation was further supported 
in HCC cells in vitro, where a direct interaction between 
HIF1α and β-catenin was shown, enhancing HIF1α signaling 
and driving EMT (78). Thus, in hypoxic conditions, HIF1α 
competes with the lymphoid enhancer factor for binding of 
transcriptional activator β-catenin inhibiting the canonical 
Wnt pathway responsible for hepatocyte proliferation and 
instead promoting adaptation, survival and EMT through HIF 
signalling (77,78). This further demonstrates the potency for 
intratumoural hypoxia to push LPC differentiation towards a 
more aggressive, therapy-resistant cancerous offspring.
Furthermore, the epithelial mesenchymal transition of 
hepatocytes could also contribute to dedifferentiation of 
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hepatocytes towards a stem/progenitor-like phenotype as seen 
in vitro (79). EMT in hypoxic conditions is probably accom-
plished by HIF mediated activation of the TGF-β pathway 
(80,81). Next to the β-catenin induced intensification, Notch1 
signaling has been shown not only essential for HIF and snail 
mediated EMT (82,83), but also capable of inducing EMT 
in normoxic conditions by directly targeting Snail in breast 
cancer cell lines (83). However, in an HCC cell line a direct 
interaction between NICD and Snail in the cytoplasm has been 
shown to result in ubiquitinylation and degradation of Snail 
(84), again, showing the complex nature of these cell-type 
specific interactions.
5. Conclusion
Despite the increase in scientific interest, the role of LPCs 
in cancer progression is still unclear. These bipotential 
progenitor cells could shift to a cancerous phenotype and give 
rise to HCC, ICC and CHC, and not only regulating tumour 
initiation and growth, but also the invasive and metastatic 
potential. Likely, specific interactions between several path-
ways involved in regulation of LPCs can be modulated by 
intrinsic as well as extrinsic factors and is capable of driving 
tumourigenesis and determining its phenotype. Of the 3 main 
liver tumours potentially derived from LPCs, CHC is most 
suitable to study the role of bipotential cells during tumour 
formation, since it consists of both hepatocyte- and cholangio-
cyte-like cells (85). We discussed a role for altered regulation 
of Notch, Wnt, HIF and TGF-β signalling in primary liver 
tumour development. Interactions between these pathways 
could possibly force a group of progenitor or cancer stem cells 
to behave differently, causing a tumour to exhibit both HCC 
and ICC-like characteristics.
There is also a potential role for hypoxia in the determi-
nation of cell fate in LPCs, possibly not only by triggering 
conversion of its tumourigenic offspring to a more malig-
nant, mixed phenotype (6,7), but also by inducing therapy 
resistance (69,86). As discussed here, the major target of 
altered signalling could be the EMT, a major process in 
malignant conversion, provoking hepatocytes to exhibit more 
stem/progenitor-like features and thus increasing the pool of 
cancer cells with an LPC signature.
These findings are of particular interest when using thera-
pies altering the signalling of one or more of these pathways, 
triggering changes which could potentially lead to more aggres-
sive tumours. More specifically, inhibiting the involvement of 
the Notch, Wnt or TGF-β pathway could be the key to altering 
the massive response to hypoxia and would allow us to reduce 
the adverse effects so often caused by hypoxia-inducing therapy.
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